Arkolith/Insider Trading/AVIR/Form 4

Hammond Janet MJ

Chief Development OfficerAtea Pharmaceuticals, Inc. (AVIR) · full profile →Form 4 · filed Feb 3, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
2 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 31, 2026Option exercise(M)58K——142K
Jan 31, 2026Tax withholding(F)14K$4.24$60K128K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2026Option exercise(M)11K—$00
Jan 31, 2026Option exercise(M)47K—$00
Jan 31, 2026Grant(A)177K—$0177K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-036270) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML